Given the notable prognostic significance of PRDX5 and its association with tumor staging and Gleason score in prostate cancer, we developed nomograms to predict patients' 3‐year and 5‐year BCR‐free survival outcomes. This evidence concerns the gene PRDX5 and Familial prostate cancer.